This is an incredibly exciting time to be in oncology,” she says. “We're seeing remarkable advances with immunotherapy in other solid tumours like melanoma and lung cancer, and I'm enthusiastic we'll have success in breast cancer too. We're on the cusp of a new era.” -- Elizabeth Mittendorf
Nature 527, S105–S107 (19 November 2015) doi:10.1038/527S105a
Vaccine. 2015 Oct 2. pii: S0264-410X(15)01376-6. doi: 10.1016/j.vaccine.2015.09.086.
Cancer vaccines in the new era of cancer immunotherapy.
Knutson KL1, Mittendorf EA2.
Biotechnol Adv. 2015 Oct 30. pii: S0734-9750(15)30048-3. doi: 10.1016/j.biotechadv.2015.10.013.
Peptide vaccines in breast cancer: The immunological basis for clinical response.
This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on animal models and phase I, phase I/II, phase II and phase III clinical trials. Peptide-based vaccines are powerful neoadjuvant immunotherapies that can directly target proteins expressed in tumor cells, mainly tumor-associated antigens (TAAs). The most common breast cancer TAA epitopes are derived from MUC1, HER2/neu and CEA proteins. Peptides derived from TAAs could be successfully used to elicit CD8 and CD4 T cell-specific responses. Thus, choosing peptides that adapt to natural variations of human leukocyte antigen (HLA) genes is critical. The most attractive advantage is that the target response is more specific and less toxic than for other therapies and vaccines. Prominent studies on NeuVax - E75 (epitope for HER2/neu and GM-CSF) in breast cancer and DPX-0907 (HLA-A2-TAAs) expressed in breast cancer, ovarian and prostate cancer have shown the efficacy of peptide-based vaccines as neoadjuvant immunotherapy against cancer. Future peptide vaccine strategies, although a challenge to be applied in a broad range of breast cancers, point to the development of degenerate multi-epitope immunogens against multiple targets.
Many disgruntled ex-employees on this board. Or ex-frustrated investors. Short Valeant. But, making money on a 1.50$ stock by shorting it? Really? Anyways.....
I think that Merck is eyeing to expand its franchise. Mayber Bayer interested in this sector, again.
I think we need to see some prelim data. I think not before 1 year before in-depth collaborations.
A stretch. But definitely possible. More on Tuesday. P.s. Where's the PR? Just peculiar that they omitted to release a PR..
Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis
Not an easy disease state to treat. One more study needed.
This is significant. Definately GALE would not have a) submitted something negative b) roll out PRs early on.
This is pre-third quarter. I think this can be the start of something fun. Let's not forget that E.Mittendorf has NOT backed down from her présentations.
Totally agree. Scam to unload their shares. Unreal. Unreal.
Synta is garbage, I guess. Useless.
Take my losses. Move on.
14th Oncology Update: Advances and Controversies
Steamboat Springs, Colorado
January 15-19, 2016
She's not stopping.
"If you look at similar vaccines that have been investigated in the metastatic setting, they have been unsuccessful. The reason for that is because the metastatic microenvironment is so hostile to the immune system. There are cells that counter immune responses and there are cytokines that dampen immune responses. If we were to ever take the vaccine into the metastatic setting, it would need to be done in combination with another immunotherapeutic agent. There has been a lot of enthusiasm about checkpoint blockades, and that could be something to be used in combination with the vaccine in the metastatic setting."
I think we are moving towards this direction.
This will be the silent trigger no one expected.....
MF is on a vendetta binge. Simple. He rehashes same old stuff and gets paid for it. Just words. No
Unfortunately, he has a plateform - a so called journalistic plateform - that allows him to say, what MF wants to say, freely. Plain POOR journalism. Unacceptable financial journalism. Useless. He has a mandate to write 1-2 articles a month on GALE - so obvious.
Thanks Dan for your reporting. It's all good info. Nothing negative. This is cancer research- long-term. Did you ask Dr M when/where her next presentation on immunotherapy would be?
A personal vendetta against GALE. Basically, editors/owners feel they lost credibility with dream-team and M. Ahn. Now, they will do anything to pay back. This is still not a good reason to have poor journalistic ethics. -----------Vendetta, pure and simple--------------------
These are two articles summarizes what was once thought impossible. Immunogenicity of breast cancer. Hmmm, isn't that Mittendorf's et al. theory?